Literature DB >> 7489568

An indicator quantitatively comparing two treatment effect sizes on responder and non-responder groups--exponential of estimated interaction parameter.

M Sugita1, T Izuno, M Kanamori, K Ogoshi, T Mitomi.   

Abstract

Sometimes a specific treatment is effective in one subgroup but not in another. An indicator allowing quantitative comparison of treatment effect in two subgroups would be useful in clinical medicine. We have developed such an indicator. It is obtained by calculations using Cox's proportional hazard or logistic model with therapy, subgroup, and confounding explanatory variables. The parameter of the interaction between therapy and subgroup can be estimated and tested statistically. The exponential value of the interaction parameter is what we tentatively call the "hazard ratio ratio", meaning the ratio between the treatment effects in two subgroups. The 95% confidence interval of the indicator can also be calculated. As a numerical example, the hazard ratio between the survival times of postoperative gastric cancer patients treated by adjuvant immunochemotherapy and patients without adjuvant immunochemotherapy in a subgroup with high serum glycosidically bound sialic acid (SA) level was lower than that in a low-SA subgroup using an estimate for hazard ratio ratio of less than 0.5 with statistical significance. We propose this indicator be used as a "responder/non-responder ratio" of therapy effect.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7489568

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  6 in total

1.  Selecting optimal treatment in clinical trials using covariate information.

Authors:  D P Byar; D K Corle
Journal:  J Chronic Dis       Date:  1977-07

2.  [Serum levels of sialic acid and other glycoproteins in stomach cancer, with special reference to cellular immunity].

Authors:  K Ogoshi; Y Kondoh; T Tajima; T Mitomi
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  1983-11

3.  The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification.

Authors:  T Kajitani
Journal:  Jpn J Surg       Date:  1981-03

4.  Glycosidically bound sialic acid levels as a predictive marker of postoperative adjuvant therapy in gastric cancer.

Authors:  K Ogoshi; Y Kondoh; T Tajima; T Mitomi
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

5.  Patient subsets and variation in therapeutic efficacy.

Authors:  R Simon
Journal:  Br J Clin Pharmacol       Date:  1982-10       Impact factor: 4.335

6.  Testing for qualitative interactions between treatment effects and patient subsets.

Authors:  M Gail; R Simon
Journal:  Biometrics       Date:  1985-06       Impact factor: 2.571

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.